Gene Editing: US Panel Review Of Vertex’s Exa-Cel To Focus On Nonclinical Assessment Of Off-Target Effects

 
• By Sue Sutter
Missed target
Vertex's analyses of off-target effects for exa-cel is the focus of an adcomm review. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers